mirvetuximab soravtansine   Click here for help

GtoPdb Ligand ID: 12250

Synonyms: Elahere® | IMGN-853 | IMGN853 | M9346A-sulfo-SPDB-DM4 | mirvetuximab soravtansine-gynx
Approved drug
mirvetuximab soravtansine is an approved drug (FDA (2022))
Compound class: Antibody
Comment: Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that delivers the cytotoxic maytansinoid DM4 (a microtubule toxin) to cancer cells that express the folate receptor α (FOLR1; P15328) [2]. FOLR1 is an active oncology drug target [8]. Mirvetuximab soravtansine has proven particularly effective against FLOR1 +ve, advanced ovarian tumours [1,4,7].
The chemical structure of DM4 and its sulfo-SPDB linker is represented in PubChem CID 131704480.
Click here for help
No information available.
Summary of Clinical Use Click here for help
The US FDA issued accelerated approval for mirvetuximab soravtansine in November 2022 [5]. This authorisation indicated mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer [7]. Drug-induced ocular (corneal) toxicity has been noted, but can be resolved with short-term topical steroid administration [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02631876 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Phase 3 Interventional ImmunoGen, Inc. 7
NCT02606305 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer Phase 1/Phase 2 Interventional ImmunoGen, Inc. 6